Early clinical trials revealed that mCRPC patients do not benefit from to PD-L1 blockade as much as patients suffering from other cancers, although 31.6% of mCRPC patients express the PD-L1 receptor (Goswami et al., 2016; Haffner et al., 2018). This evidence concerns the gene CD274 and cancer.